⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Robert Wesolowski Hope S. Rugo Jennifer M. Specht Hyo S. Han Peter Kabos Ulka N. Vaishampayan Seth A. Wander Keerthi Gogineni Alexander I. Spira Anne F. Schott Maysa Abu‐Khalaf Sarah C. Mutka Samuel Suzuki Brian Sullivan Igor Gorbatchevsky Rachel M. Layman

View at Publisher

Ask AI

Bookmark

Share

Key Points

The analysis population includes patients with advanced breast cancer receiving no prior systemic therapy.
Key characteristics such as demographic data and baseline disease status were documented for targeted therapies.
Median ages and disease stages were compared, supporting insights into treatment efficacy.
Reflects findings on the combination therapy of gedatolisib, palbociclib, and letrozole in clinical practice.

Implication

Analysis reports patient characteristics in those with hormone receptor-positive, HER2-negative breast cancer, highlighting treatment responses.

Abstract

Patient demographic and baseline disease characteristics in the full analysis population with no prior systemic therapy for advanced breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wesolowski et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a97 https://doi.org/10.1158/1078-0432.30255523

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
2Table 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
3Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
4Table 4 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
5Figure 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025

Data from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer2025
Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer2025